TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Kintor Pharmaceutical Ltd ( (HK:9939) ) has provided an update.
Kintor Pharmaceutical Limited announced that its long-term safety phase III clinical trial for KX-826, a potential first-in-class treatment for androgenetic alopecia (AGA), has successfully reached its primary endpoint. The trial, conducted across 16 clinical research centers in China, demonstrated statistically significant and clinically meaningful outcomes, indicating excellent safety and efficacy of the KX-826 tincture. This development could enhance Kintor’s positioning in the pharmaceutical industry, particularly in the AGA treatment market, and may have positive implications for stakeholders.
More about Kintor Pharmaceutical Ltd
Kintor Pharmaceutical Limited is a pharmaceutical company incorporated in the Cayman Islands, focusing on the development of innovative treatments. The company is engaged in the research and development of drugs, particularly in the field of androgenetic alopecia (AGA) and other related conditions.
YTD Price Performance: 17.53%
Average Trading Volume: 1,428,026
Technical Sentiment Consensus Rating: Buy
Current Market Cap: HK$519.5M
For detailed information about 9939 stock, go to TipRanks’ Stock Analysis page.